The role of the FHIT/FRA3B locus in cancer

Annual Review of Genetics

Volumn 32, Issue , 1998, Pages 7-31

  Huebner, Kay ^a   Garrison, Preston N ^b   Barnes, Larry D ^b   Croce, Carlo M ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Diadenosine polyphosphate hydrolases; Environmental carcinogens; Fragile sites; HIT gene family; Kidney carcinoma; Lung carcinoma; Tumor suppressor

Indexed keywords

CANCER; CARCINOGENESIS; CHROMOSOME 3P; GENE LOCUS; GENE MAPPING; HUMAN; KIDNEY CARCINOMA; LUNG CARCINOMA; PRIORITY JOURNAL; REVIEW; STOMACH CARCINOMA; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CARCINOMA;

ACID ANHYDRIDE HYDROLASES; ALLELES; AMINO ACID SEQUENCE; CHROMOSOME FRAGILE SITES; CHROMOSOME FRAGILITY; CHROMOSOMES, HUMAN, PAIR 3; FEMALE; GENE DELETION; GENE REARRANGEMENT; GENES, TUMOR SUPPRESSOR; HOMOZYGOTE; HUMANS; MALE; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; NEOPLASMS; PHYSICAL CHROMOSOME MAPPING; PROTEINS; RNA, NEOPLASM;

EID: 0032413191     PISSN: 00664197     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.genet.32.1.7     Document Type: Review

References (92)

1. Ahmadian M, Wistuba II, Fong KM, Behrens C, Kodagoda DR, et al. 1997. Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions and familial breast cancer probands. Cancer Res. 57:3664-68
2. 3-triphosphate hydrolase. Biochemistry 35: 11529-35
3. Boldog F, Gemmill RM, West J, Robinson M, Robinson L, et al. 1997. Chromosome 3p14 homozygous deletions and sequence analysis of FRA3B. Hum. Mol. Genet. 6:193-203
4. Boldog FL, Gemmill RM, Wilke CM, Glover TW, Nilsson AS, et al. 1993. Positional cloning of the hereditary renal carcinoma 3;8 chromosome translocation breakpoint. Proc. Natl. Acad. Sci. USA 90: 8509-13
5. Boldog FL, Waggoner B, Glover TW, Chumakov I, Le Paslier D, et al. 1994. Integrated YAC contig containing the 3p14.2 hereditary renal carcinoma 3;8 translocation breakpoint and the fragile site FRA3B. Genes Chromosomes Cancer 11:216-21
6. 4-tetraphosphate α,β-phosphorylase. J. Biol. Chem. 270: 19377-82
7. Brenner C, Garrison P, Gilmour J, Peisach D, Ringe D, et al. 1997. Crystal structures of HINT demonstrate that histidine triad proteins are GalT-related nucleotide-binding proteins. Nat. Struct. Biol. 4:231-38
8. Brevet A, Chen J, Fromant M, Blanquet S, Plateau P. 1991. Isolation and characterization of a dinucleoside triphosphatase from Saccharomyces cerevisiae. J. Bacteriol. 173:5275-79
9. Brzoska PM, Chen H, Levin NA, Kuo WL, Collins C, et al. 1996. Cloning, mapping, and in vivo localization of a human member of the PKCI-1 protein family (PRKCNH1). Genomics 36:151-56
10. Cohen AJ, Li FP, Berg S, Marchetto DJ, Tsai S, et al. 1979. Hereditary renal-cell carcinoma associated with a chromosomal translocation. N. Engl. J. Med. 301:592-95
11. Coquelle A, Pipiras E, Toledo F, Buttin G, Debatisse M. 1997. Expression of fragile sites triggers intrachromosomal mammalian gene amplification and sets boundaries to early amplicons. Cell 89:215-25
12. Druck T, Hadaczek P, Fu T-B, Ohta M, Siprashvili Z, et al. 1997. Structure and expression of the human FHIT gene in normal and tumor cells. Cancer Res. 57:504-12
13. Druck T, Kastury K, Hadaczek P, Podolski J, Toloczko A, et al. 1995. Loss of heterozygosity at the familial RCC t(3;8) locus in most clear cell renal carcinomas. Cancer Res. 55:5348-53
14. Field TL, Reznikoff WS, Frey PA. 1989. Galactose-1-phosphate uridylyltransferase: identification of histidine-164 and histidine-166 as critical residues by site-directed mutagenesis. Biochemistry 28:2094-99
15. Fleckner J, Rasmussen HH, Justesen J. 1991. Human interferon gamma potently induces the synthesis of a 55-kDa protein (gamma 2) highly homologous to rabbit peptide chain release factor and bovine tryptophanyl-tRNA synthetase. Proc. Natl. Acad. Sci. USA 88:11520-24
16. Fong KM, Biesterveld EJ, Virmani A, Wistuba I, Sekido Y, et al. 1997. FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations. Cancer Res. 57:2256-67
17. Fraser CM, Gocayne JD, White O, Adams MD, Clayton RA, et al. 1995. The minimal gene complement of Mycoplasma genitalium. Science 270:397-403
18. Frey PA, Wong L-J, Sheu K-F, Yank S-L. 1982. Galactose-1-phosphate uridylyltransferase: detection, isolation, and characterization of the uridylyl enzyme. Methods Enzymol. 87:20-36
19. Gayther SA, Barski P, Batley SJ, Li L, de Foy KA, et al. 1997. Aberrant splicing of the TSG101 and FHIT genes occurs frequently in multiple malignancies and in normal tissues and mimics alterations previously described in tumours. Oncogene 15:2119-26
20. Gemma A, Hagiwara K, Ke Y, Burke LM, Khan MA, et al. 1997. FHIT mutations in human primary gastric cancer. Cancer Res. 57:1435-37
21. Gilmour J, Liang N, Lowenstein JM. 1997. Isolation, cloning and characterization of a low-molecular-mass purine nucleoside-and nucleotide-binding protein. Biochem. J. 326:471-77
22. Glover TW. 1998. Common fragile sites. In Genetic Instabilities and Neurological Disease, ed. RD Wells, ST Warren. San Diego: Academic. In press
23. Glover TW, Berger C, Coyle J, Echo B. 1984. DNA polymerase a inhibition by aphidicolin induced gaps and breaks at common fragile sites in human chromosomes. Hum. Genet. 67:136-42
24. Glover TW, Coyle-Morris JF, Frederick PL, Brown RS, Berger CS, et al. 1988. Translocation t(3;8) (p14.2;q24.1) in renal cell carcinoma affects expression of the common fragile site at 3p14 (FRA3B) in lymphocytes. Cancer Genet. Cytogenet. 31:69-73
25. Glover TW, Stein CK. 1988. Chromosome breakage and recombination at fragile sites. Am. J. Hum. Genet. 43:265-73
26. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, et al. 1994. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet. 7:85-90
27. Greenspan DL, Connolly DC, Wu R, Lei RY, Vogelstein JTC, et al. 1997. Loss of FHIT expression in cervical carcinoma cell lines and primary tumors. Cancer Res. 57:4692-98
28. Hadaczek P, Podolski J, Toloczko A, Kurzawski G, Sikorski A, et al. 1996. Accumulation of losses at 3p common deletion sites is characteristic of clear cell renal cell carcinoma. Virchows Arch. 429:37-42
29. Hadaczek P, Siprashvili Z, Markiewski M, Domagala W, Druck T, et al. 1998. Absence or reduction of Fhit expression in most clear cell renal carcinomas. Cancer Res. 58:2946-51
30. Hendricks DT, Taylor R, Reed M, Birrer MJ. 1997. FHIT gene expression in human ovarian, endometrial, and cervical cancer cell lines. Cancer Res. 57:2112-15
31. Holm L, Sander C. 1997. Enzyme HIT. Trends Biochem. Sci. 22:116-17
32. 4A) asymmetrical hydrolase: sequence similarity with the histidine triad (HIT) protein family. Biochem. J. 312:925-32
33. Iliopoulos O, Kibel A, Gray S, Kaelin WG. 1995. Tumour suppression by the human von Hippel-Lindau gene product. Nat. Med. 1:822-26
34. Inoue H, Ishii H, Alder H, Snyder E, Druck T, et al. 1997. Sequence of the FRA3B common fragile region: implications for the mechanism of FHIT deletion. Proc. Natl. Acad. Sci. USA 94:14584-89
35. Kastury K, Baffa R, Druck T, Ohta M, Cotticelli MG, et al. 1996. Potential gastrointestinal tumor suppressor locus at the 3p14.2 FRA3B site identified by homozygous deletions in tumor cell lines. Cancer Res. 56:978-83
36. Kastury K, Ohta M, Lasota J, Moir D, Dorman T, et al. 1996. Structure of the human receptor tyrosine phosphatase gamma gene (PTPRG) and relation to the familial RCC t(3;8) chromosome translocation. Genomics 32:225-35
37. 4A) binding fraction in Escherichia coli is a member of histidine triad (HIT) protein family. Res. Commun. Biochem. Cell Mol. Biol. 1:157-70
38. Kovatich A, Friedland DM, Druck T, Hadaczek P, Huebner K, et al. 1998. Human chromosome 3p alterations in neuroendocrine lung tumors. Cancer 83:1109-17
39. Larson AA, Kern S, Curtiss S, Gordon R, Cavenee WK, et al. 1997. High resolution analysis of chromosome 3p alterations in cervical carcinoma. Cancer Res. 57:4082-90
40. Larson AA, Liao S-Y, Stanbridge EJ, Cavenee WK, Hampton GM. 1997. Genetic alterations accumulate during cervical tumorigenesis and indicate a common origin for multifocal lesions. Cancer Res. 57:4147-76
41. Latif F, Tory K, Gnarra J, Yao M, Duh F-M, et al. 1993. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260:1317-20
42. 4A); their enzymatic synthesis and degradation. Nucleic Acids Res. 18:6083-88
43. Lima CD, D'Amico KL, Naday I, Rosenbaum G, Westbrook EM, et al. 1997. MAD analysis of FHIT, a putative human tumor suppressor from the HIT protein family. Structure 5:763-74
44. Lima CD, Klein MG, Hendrickson WA. 1997. Structure-based analysis of catalysis and substrate definition in the HIT protein family. Science 278:286-90
45. Lima CD, Klein MG, Weinstein IB, Hendrickson WA. 1996. Three dimensional structure of human protein kinase C interacting protein 1, a member of the HIT family of proteins. Proc. Natl. Acad. Sci. USA 93:5357-62
46. Lin P-M, Liu T-C, Chang J-G, Chen T-P, Lin S-F. 1997. Aberrant FHIT transcripts in acute myeloid leukaemia. Br. J. Haematol. 99:612-17
47. Lisitsyn NA, Lisitsina NM, Dalbagni G, Barker P, Sanchez CA, et al. 1995. Comparative genomic analysis of tumors: detection of DNA losses and amplification. Proc. Natl. Acad. Sci. USA 92:151-55
48. Lubinski J, Hadaczek P, Podolski J, Toloczko A, Sikorski A, et al. 1994. Common regions of deletion in chromosome regions 3p12 and 3p14.2 in primary clear cell renal carcinomas. Cancer Res. 54:3710-13
49. Lux A, Bardenheuer W, Michael D, Brocker F, Julicher K, et al. 1997. Identification of novel expressed sequence tags within the FHIT gene locus in human chromosome 3p14.2. Hum. Genet. 100:90-95
50. Mandai M, Konishi I, Kuroda H, Nanbu K, Matsushita K, et al. 1998. Expression of abnormal transcripts of the FHIT gene in ovarian carcinoma. Eur. J. Cancer, In press
51. Mao L, Lee JS, Kurie JM, Fan YH, Lippman SM, et al. 1997. Clonal genetic alterations in the lungs of current and former smokers. J. Natl. Cancer Inst. 89:857-62
52. 3A) as a substrate and a product of mammalian tryptophanyl-tRNA synthetase. FEBS Lett. 350:287-90
53. 4-tetraphosphate phosphorylase activity. Biochem. J. 320:795-800
54. Michael D, Beer DG, Wilke CW, Miller DE, Glover TW. 1997 Frequent deletions of FHIT and FRA3B in Barrett's metaplasia and esophageal adenocarcinomas. Oncogene 15:1553-59
55. Negrini M, Monaco C, Vorechovsky I, Ohta M, Druck T, et al. 1996. The FHIT gene at 3p14.2 is abnormal in breast carcinomas. Cancer Res. 56:3173-79
56. Nelson HH, Wiencke JK, Gunn L, Wain JC, Christiani DC, et al. 1998. Chromosome 3p14 alterations in lung cancer: evidence that FHIT exon deletion is a target of tobacco carcinogens and asbestos. Cancer Res. 58:1804-7
57. Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, et al. 1996. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 84:587-97
58. Ong ST, Fong KM, Bader SA, Minna JD, Le Beau MM, et al. 1997. Precise localization of the FHIT gene to the common fragile site at 3p14.2 (FRA3B) and characterization of homozygous deletions within FRA3B that affect FHIT transcription in tumor cell lines. Genes Chromosomes Cancer 20:16-23
59. Pace HC, Garrison PN, Barnes LD, Draganescu A, Ashton PR, et al. 1998. Genetic, biochemical and crystallographic definition of a substrate analog complex with the fragile histidine triad protein as the active signaling form of Fhit. Proc. Natl. Acad. Sci. USA 95:5484-89
60. Panagopoulos I, Pandis N, Thelin S, Petersson C, Mertens F, et al. 1996. The FHIT and PTPRG genes are deleted in benign proliferative breast disease associated with familial breast cancer and cytogenetic rearrangements of chromosome band 3p14. Cancer Res. 56:4871-75
61. Panagopoulos I, Thelin S, Mertens F, Mitelman F, Aman P. 1997. Variable FHIT transcripts in non-neoplastic tissues. Genes Chromosomes Cancer 19:215-19
62. Paradee W, Mullins C, He Z, Glover T, Wilke C, et al. 1995. Precise localization of aphidicolin-induced breakpoints on the short arm of human chromosome 3. Genomics 27:358-61
63. Paradee W, Wilke CM, Wang L, Shridhar R, Mullins CM, et al. 1996. A 350-kb cosmid contig in 3p14.2 that crosses the t(3;8) hereditary renal cell carcinoma translocation breakpoint and 17 aphidicolin-induced FRA3B breakpoints. Genomics 35:87-93
64. Pearson JD, Dewald DB, Mathews WR, Mozier NM, Zurcher-Neely HA, et al. 1990. Amino acid sequence and characterization of a protein inhibitor of protein kinase C. J. Biol. Chem. 265:4583-91
65. Popescu NC. 1994. Chromosome fragility and instability in human cancer. Crit. Rev. Oncog. 5:121-40
66. Rassool FV, Le Beau MM, Neilly ME, van Melle E, Espinosa R, et al. 1992. Increased genetic instability of the common fragile site at 3p14 after integration of exogenous DNA. Am. J. Hum. Genet. 50:1243-51
67. Rassool FV, LeBeau MM, Shen M-L, Neilly ME, Espinosa R III, et al. 1996. Direct cloning of DNA sequences from the common fragile site region at chromosome band 3p14.2. Genomics 35:109-17
68. Rassool FV, McKeithan TW, Neilly ME, van Melle E, Espinosa R, et al. 1991. Preferential integration of marker DNA into the chromosomal fragile site at 3p14.2: a novel approach to cloning fragile sites. Proc. Natl. Acad. Sci. USA 88:6657-61
69. Richards RI, Sutherland GR. 1997. Dynamic mutation: possible mechanisms and significance in human disease. Trends Biochem. Sci. 22:432-36
70. Robinson K, Jones D, Howell S, Soneji Y, Martin S, et al. 1994. Expression and characterization of maize ZPB14, a member of a new family of zinc-binding proteins. Biochem. J. 307:267-72
71. Séraphin B. 1992. The HIT protein family: a new family of proteins present in prokaryote yeast and mammals. DNA Seq. 3:177-79
72. Shridhar R, Shridhar V, Wang X, Paradee W, Dugan M, et al. 1996. Frequent breakpoints in the 3p14.2 fragile site, FRA3B, in pancreatic tumors. Cancer Res. 56:4347-50
73. Shridhar V, Wang L, Rosati R, Paradee W, Shridhar R, et al. 1997. Frequent breakpoints in the region surrounding FRA3B in sporadic renal cell carcinomas. Oncogene 14:1269-77
74. Shuin T, Kondo K, Torigoe S, Kishida T, Kubota Y, et al. 1994. Frequent somatic mutations and loss of heterozygosity of the von Hippel Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res. 54:2852-55
75. Siprashvili Z, Sozzi G, Barnes LD, McCue P, Robinson AK, et al. 1997. Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc. Natl. Acad. Sci. USA 94:13771-76
76. Simon B, Bartsch D, Barth P, Prasnika N, Munch K, et al. 1998. Frequent abnormalities of the putative tumor suppressor gene FHIT at 3p14.2 in pancreatic carcinoma cell lines. Cancer Res. 58:1583-87
77. Sozzi G, Tornielli S, Tagliabue E, Sard L, Pezzella F, et al. 1997. Absence of Fhit protein in primary lung tumors and cell lines with FHIT gene abnormalities. Cancer Res. 57:5207-12
78. Sozzi G, Veronese ML, Negrini M, Baffa R, Cotticelli MG, et al. 1996. The FHIT gene at 3p14.2 is abnormal in lung cancer. Cell 85:17-26
79. Sugimoto K, Yamada K, Miyagawa K, Hirai H, Oshimi K. 1997. Decreased or altered expression of the FHIT gene in human leukemias. Stem Cells 15:223-28
80. 4A are primers for oligoadenylate synthesis catalyzed by interferon-inducible 2-5 A synthetase. FEBS Lett. 408:177-81
81. van den Berg A, Draaijers TG, Kok K, Timmer T, Van der Veen AY, et al. 1997. Normal FHIT transcripts in renal cell cancer-and lung cancer-derived cell lines, including a cell line with a homozygous deletion in the FRA3B region. Genes Chromosomes Cancer 19:220-27
82. Virgilio L, Schuster M, Gollin SM, Veronese ML, Ohta M, et al. 1996. FHIT gene alterations in head and neck squamous cell carcinomas. Proc. Natl. Acad. Sci. USA 93:9770-75
83. Wang L, Paradee W, Mullins C, Shridhar R, Rosati R, et al. 1997. Aphidicolin-induced FRA3B breakpoints cluster in two distinct regions. Genomics 41:485-88
84. Wedekind JE, Frey PA, Rayment I. 1995. Three-dimensional structure of galactose-1-phosphate uridylyltransferase from Escherichia coli at 1.8 Å resolution. Biochemistry 34:11049-61
85. Wedekind JE, Frey PA, Rayment I. 1996. The structure of nucleotidylated histidine 166 of galactose-1-phosphate uridylyltransferase provides insight into phosphoryl group transfer. Biochemistry 35:11560-69
86. Wilke CM, Guo S-W, Hall BK, Boldog F, Gemmill RM, et al. 1994. Multicolor FISH mapping of YAC clones in 3p14 and identification of a YAC spanning both FRA3B and the t(3;8) associated with hereditary renal cell carcinoma. Genomics 22:319-26
87. Wilke MC, Hall BK, Hoge A, Paradee W, Smith DI, et al. 1996. FRA3B extends over a broad region and contains a spontaneous HPV integration site: direct evidence for the coincidence of viral integration sites and fragile sites. Hum. Mol. Genet. 5:187-95
88. Wistuba II, Lam S, Behrens C, Virmani AK, Fong KM, et al. 1997. Molecular damage in the bronchial epithelium of current and former smokers. J. Natl. Cancer Inst. 89:1366-73
89. Wistuba II, Montellano FD, Milchgrub S, Virmani AK, Behrens C, et al. 1997. Deletions of chromosome 3p are frequent and early events in the pathogenesis of uterine cervical carcinoma. Cancer Res. 57:3154-58
90. Xiao G-H, Jin F, Klein-Szanto AJP, Goodrow TL, Linehan MW, et al. 1997. The FHIT gene product is highly expressed in the cytoplasm of renal tubular epithelium and is down-regulated in kidney cancers. Am. J. Pathol. 151:1541-47
91. Yunis JJ, Soreng AL. 1984. Constitutive fragile sites and cancers. Science 226: 1199-204
92. Zimonjic DB, Druck T, Ohta M, Kastury K, Popescu NC, et al. 1997. Positions of chromosome 3p14.2 fragile sites (FRA3B) within the FHIT gene. Cancer Res. 57:1166-70